Obesity-fighting drugs may reduce alcohol consumption in individuals with alcohol use disorder

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalizations among individuals with alcohol use disorder, AUD.